Dental Technologies Inc. MARCS-CMS 612599 — September 02, 2026

CLOSEOUT LETTER

• Delivery Method: Via Electronic Mail - Return Receipt Requested
• Product: Drugs

---

• Recipient: Mr. Stephen A Erickson; President; Dental Technologies Inc.; 6901 N Hamlin Ave; Lincolnwood, IL 60712; United States; serickson@dentaltech.com

• Issuing Office: Division of Pharmaceutical Quality Operations III; United States

---

Dear Mr. Erickson

The U.S. Food and Drug Administration (FDA) has completed an evaluation of your firm’s corrective actions in response to our Warning Letter, dated November 30, 2021. Based on our evaluation, it appears that you have adequately addressed the violations contained in this Warning Letter.

This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.

Sincerely,
/S/
Brian Nicholson
Brian Nicholson
Compliance Officer, Division of Drug Quality I
Office of Manufacturing Quality
Office of Compliance
Center for Drug Evaluation and Research

Cc: Paula Erickson | Vice President
perickson@dentaltech.com